Specialty pharmaceutical manufacturers, which typically produce low-volume, high-value drugs, such as medicines for rare diseases and cell and gene therapies, are facing expanded product verification requirements under the final phase of the U.S. Drug Supply Chain Security Act (DSCSA).
In this article, we'll explain why specialty drug manufacturers need a product verification solution even if they do not accept returns, do not expect to be part of suspect product investigations, and do not expect a high number of product verification requests.
We'll also explain why TraceLink Product Information Manager - Product Verification, a proven digital network-based product verification solution that provides responses to product verification requests from direct and indirect trade partners in less than one second, is the fastest, most effective, and most cost-efficient way to comply with these requirements. Read more >
TraceLink’s network platform, with Integrate Once, Interoperate with Everyone™ capability, revolutionizes compliance and operational efficiency for dispensing customers. By seamlessly connecting with an expansive digital network of supply chain partners, TraceLink ensures robust compliance with the Drug Supply Chain Security Act (DSCSA), swiftly manages compliance exceptions, and enables streamlined digital recalls. Furthermore, its advanced analytics capabilities facilitate the prediction of drug shortages, enhancing supply chain resilience. This integration offers pharmacies, hospitals, and other dispensers a comprehensive solution that not only meets regulatory demands but also optimizes inventory management and maintains the integrity of the drug supply, ensuring patient safety and continuity of care.
